Levomepromazine

CHEMBL1764 Phase 4 Approved Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

328.5 g/mol

LogP

4.7

Phase

4

This phenothiazine antipsychotic and sedative is used to treat psychosis, severe anxiety, agitation, and to provide pain relief and sedation in palliative care settings. It has both antipsychotic and antiemetic properties, making it useful for nausea and vomiting as well.

Molecular Weight

328.5000 g/mol

LogP

4.70

TPSA

41.00 Å²

Lipinski RO5

Pass

Therapeutic Areas

Bipolar Disorder Generalized Anxiety Disorder Schizophrenia

Mechanism of Action

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

2D Structure

SVG PNG

Cite this structure

Embed this structure

SMILES

COc1ccc2c(c1)N(C[C@H](C)CN(C)C)c1ccccc1S2

InChI

InChI=1S/C19H24N2OS/c1-14(12-20(2)3)13-21-16-7-5-6-8-18(16)23-19-10-9-15(22-4)11-17(19)21/h5-11,14H,12-13H2,1-4H3/t14-/m1/s1

Molecular Formula

C19H24N2OS

HBD / HBA

- / 4

Rotatable Bonds

5

Heavy Atoms

23

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

This phenothiazine antipsychotic and sedative is used to treat psychosis, severe anxiety, agitation, and to provide pain relief and sedation in palliative care settings. It has both antipsychotic and antiemetic properties, making it useful for nausea and vomiting as well.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Levomepromazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1764. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 72287. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Looking for patient-friendly information?

Levomepromazine on PillFYI

Structure

Quick Data

Formula: C19H24N2OS

External Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.